Catalent Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 1/6

Catalent şirketinin toplam hissedar öz sermayesi $3.6B ve toplam borcu $4.6B olup, bu da borç-öz sermaye oranını 126.9% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $9.8B ve $6.1B dir. Catalent 'in FAVÖK'ü $6.0M faiz karşılama oranı 0 dur. Şirketin $289.0M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

126.9%

Borç/özkaynak oranı

US$4.57b

Borç

Faiz karşılama oranı	0.02x
Nakit	US$289.00m
Eşitlik	US$3.60b
Toplam yükümlülükler	US$6.15b
Toplam varlıklar	US$9.75b

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 0C8 'nin kısa vadeli varlıkları ( $2.6B ) kısa vadeli yükümlülüklerini ( $1.0B ) aşıyor.

Uzun Vadeli Yükümlülükler: 0C8 'un kısa vadeli varlıkları ( $2.6B ) uzun vadeli yükümlülüklerini ( $5.1B ) karşılamamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 0C8 'nin net borç/öz sermaye oranı ( 118.9% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: 0C8 şirketinin borç/öz sermaye oranı son 5 yılda 122% seviyesinden 126.9% seviyesine yükseldi.

Borç Kapsamı: 0C8 'nin borcu işletme nakit akışı ( 5.9% ) tarafından iyi bir şekilde karşılanmıyor.

Faiz Kapsamı: 0C8 'in borcuna ilişkin faiz ödemeleri EBIT ( 0 x kapsam) tarafından iyi karşılanmıyor.

Catalent Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 1/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Catalent, Inc. announced delayed annual 10-K filing

Catalent, Inc. announced delayed 10-Q filing

Catalent, Inc. announced delayed 10-Q filing

Catalent Receives NYSE Notice Regarding Late Form 10-K Filing

Catalent, Inc. announced delayed annual 10-K filing

Catalent Regains Compliance with NYSE Continued Listing Standards

Recent updates

Catalent, Inc. announced delayed annual 10-K filing

Full year 2024 earnings released: US$5.76 loss per share (vs US$1.41 loss in FY 2023)

New minor risk - Insider selling

Insufficient new directors

Catalent, Inc. announced delayed 10-Q filing

Novo Holdings A/S entered into an agreement to acquire Catalent, Inc. (NYSE:CTLT) from Elliott Investment Management L.P. and other for $11.7 million.

Novo Holdings A/S entered into an agreement to acquire Catalent, Inc. (NYSE:CTLT) from Elliott Investment Management L.P. and other for $11.7 million.

Catalent, Inc. to Report Q2, 2024 Results on Feb 09, 2024

Catalent, Inc. Announces Executive Changes

Catalent, Inc., Annual General Meeting, Jan 25, 2024

Catalent, Inc. Reaffirms Earnings Guidance for the Fiscal Year 2024

Catalent, Inc. announced delayed 10-Q filing

Catalent, Inc. to Report Q1, 2024 Results on Nov 15, 2023

Catalent, Inc. Appoints David McErlane as Group President of Catalent’s Biologics segment, Effective September 25, 2023

Catalent Receives NYSE Notice Regarding Late Form 10-K Filing

Catalent, Inc. Appoints Steven Barg as A Member of the Board of Directors

Catalent, Inc. announced delayed annual 10-K filing

Full year 2023 earnings released: US$1.28 loss per share (vs US$2.74 profit in FY 2022)

Catalent, Inc. Announces Board Changes

Catalent, Inc. to Report Q4, 2023 Results on Aug 29, 2023

Insufficient new directors

Catalent, Inc. Announces Executive Changes

Catalent, Inc.(NYSE:CTLT) dropped from Russell 1000 Growth Index

Catalent, Inc. Appoints Matti Masanovich as Senior Vice President, Effective July 5, 2023

Catalent Regains Compliance with NYSE Continued Listing Standards

Catalent, Inc. Reports Impairment Results for the Quarter Ended March 31, 2023

Catalent, Inc. Updates Revenue Guidance for the Full Year of 2023

Catalent, Inc. announced delayed 10-Q filing

Now 37% undervalued after recent price drop

Catalent, Inc. Reduces Revenue Guidance for the Fiscal Year 2023

Insider recently sold €66k worth of stock

Investor sentiment improves as stock rises 18%

Now 22% undervalued after recent price drop

Catalent Appoints Joseph A. Ferraro as Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary

Catalent, Inc. Reiterates Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings released: EPS: US$0.45 (vs US$0.51 in 2Q 2022)

Danaher Reportedly Expresses Takeover Interest in Catalent

Investor sentiment improves as stock rises 36%

Catalent, Inc. to Report Q2, 2023 Results on Feb 07, 2023

Now 20% undervalued after recent price drop

Catalent, Inc. Announces the Appointment of Ricardo Zayas as Senior Vice President, Operations, Biologics North America

Catalent, Inc. Announces Director Changes

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Insider recently sold €163k worth of stock

First quarter 2023 earnings released

Catalent, Inc. Revises Revenue Guidance for the Full Year 2023

Catalent, Inc. to Report Q1, 2023 Results on Nov 01, 2022

Catalent, Inc. (NYSE:CTLT) acquired Metrics, Inc. from Mayne Pharma Group Limited (ASX:MYX) for approximately $480 million.

Catalent, Inc. Appoints Karen Santiago as Chief Accounting Officer

Now 21% undervalued after recent price drop

Catalent, Inc., Annual General Meeting, Oct 27, 2022

Full year 2022 earnings released: EPS: US$2.86 (vs US$3.15 in FY 2021)

Catalent, Inc. Appoints Karen Flynn to Board of Directors, Effective September 15, 2022

Executive Chair of the Board recently sold €4.0m worth of stock

Catalent, Inc. (NYSE:CTLT) agreed to acquire Metrics, Inc. from Mayne Pharma (USA), Inc. for $475 million.

Catalent, Inc. to Report Q4, 2022 Results on Aug 29, 2022

Executive Chair of the Board recently sold €1.0m worth of stock

Catalent, Inc. Announces Board Changes

Catalent, Inc. Raises Revenue Guidance for the Full Year of 2022

Third quarter 2022 earnings released: EPS: US$0.78 (vs US$1.27 in 3Q 2021)

Insufficient new directors

Catalent, Inc. (NYSE:CTLT) acquired Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. to Report Q3, 2022 Results on May 03, 2022

Catalent, Inc. revises Earnings Guidance for the Fiscal Year 2022

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Independent Director recently sold €573k worth of stock